Reports

- Global Locations -

Headquarters

Future Market Insights, Inc.

Christiana Corporate, 200
Continental Drive, Suite 401,
Newark, Delaware - 19713,
United States

T: +1-347-918-3531

Americas

Future Market Insights, Inc.

616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States

MEA

Future Market Insights

1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates

Europe

Future Market Insights

3rd Floor, 207 Regent Street,
W1B 3HH London
United Kingdom

T: + 44 (0) 20 8123 9659

Asia Pacific

Future Market Insights

IndiaLand Global Tech Park, Unit UG-1, Behind Grand HighStreet, Phase 1, Hinjawadi, MH, Pune – 411057, India

Asthma Treatment Market Outlook from 2024 to 2034

Future Market Insights (FMI)’ updated report on the asthma treatment market highlights several opportunities and growth prospects for the coming decade. As per the report, the asthma treatment market is set to surge from US$ 28.0 billion in 2024 and US$ 46.0 billion by 2034. The report reflects a robust CAGR of 5.1% between 2024 and 2034, inferring strong market growth.

Attributes Key Insights
Global Asthma Treatment Market Size (2024E) US$ 28.0 billion
Market Value (2034F) US$ 46.0 billion
Value-based CAGR (2024 to 2034) 5.1%

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

High Asthma Prevalence - A Key Factor Surging Asthma Treatment Adoption

The increasing incidence of asthma, growing knowledge about asthma medications, and advancements in asthma treatment choices are projected to spur market growth. The industry is further propelled by environmental factors such as air pollution, allergens, and lifestyle changes, which contribute to the surged prevalence of asthma worldwide.

Precision medicine is gaining traction in the asthma treatment industry as demand for individualized asthma medications increases. Mobile applications, smart inhalers, and wearable devices are improving tailored asthma therapy by allowing for real-time monitoring of symptoms, medication adherence, and lung function.

This accurate data gathering helps healthcare practitioners and professionals to understand each patient's asthma management better and offer appropriate treatment solutions.

Remote monitoring and telemedicine services are further estimated to enhance personalized treatment for patients in remote and underdeveloped areas. Pharmaceutical companies and research organizations are investing in innovating new drugs and therapies to meet the diverse needs of asthma patients globally.

Public health initiatives and awareness campaigns are further boosting market development. Urbanization, industrialization, genetic susceptibility, and family history of asthma are set to contribute to mounting asthma prevalence, creating an environment favorable for market growth.

Analysis of Historical Trends in Global Asthma Treatment Market Growth

From 2019 to 2023, bronchodilators such as theophylline and beta-agonists were primarily considered as asthma treatments, providing relief from symptoms. During 2019 and 2023, the market grew at a CAGR of 6.8%. Development in genetics and biomarker research has enabled personalized asthma treatment, optimizing its efficacy and minimizing side effects.

Digital health technologies, such as asthma management mobile apps, smart inhalers, and telemedicine services, further enabled better monitoring of asthma symptoms, medication adherence, and remote patient management.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Key Asthma Treatment Market Trends

Smart inhalers, smartphone applications, and telemedicine are improving asthma therapy by allowing for remote monitoring, medication adherence, and increased patient awareness and education. Preventive methods, such as environmental trigger reduction and lifestyle modifications aimed at reducing exacerbations and improving long-term treatment results, are set to fuel the market development.

Combination inhalers with bronchodilators and corticosteroids are gaining traction in asthma management due to their ease of use and improved patient outcomes. Healthcare policies, reimbursement structures, and value-based care initiatives are set to fuel asthma treatment adoption globally.

Leading companies and producers are focusing on developing novel therapeutic targets, drug delivery systems, and alternative treatments, propelling market development. The shift toward patient-centric care models, self-management education, and empowerment is gaining momentum in several emerging markets.

Comparative View of Adjacent Markets

The nitric oxide asthma testing market and the severe asthma treatment market have both been studied by Future Market Insights (FMI). The data depict the projected growth of the asthma treatment market from 2024 to 2034 with regard to other markets.

Asthma Treatment Market:

Attributes Asthma Treatment Market
CAGR (2024 to 2034) 5.1%
Opportunities for Market Development and Collaboration in the Global Asthma Treatment Industry Rising government funding, subsidies, awareness programs, and efforts are projected to create ample opportunities for manufacturers in the market.
Trends in Respiratory Drug Development and Regulatory Approvals in the Asthma Treatment Market Biologic drugs targeting inflammatory pathways, such as IL-5 or IgE, are increasingly used in asthma treatment, providing targeted relief and improving lung function.

Nitric Oxide Asthma Testing Market:

Attributes Nitric Oxide Asthma Testing Market
CAGR (2024 to 2034) 4.7%
Growth Factor Due to the rising prevalence of asthma worldwide, the demand for nitric oxide asthma testing is increasing, generating opportunities for producers and leading companies.
Key Trends Technological developments are improving the accuracy and user-friendliness of nitric oxide testing devices, leading to improved diagnostic accuracy and patient outcomes.

Severe Asthma Treatment Market:

Attributes Severe Asthma Treatment Market
CAGR (2024 to 2034) 5.1%
Growth Factor Digital health technologies such as smart inhalers, mobile apps, and telemedicine are gaining traction in the market as they support remote monitoring, self-management, and treatment adherence in severe asthma patients.
Key Trends Research and development activities are evolving novel asthma therapies, including small molecule inhibitors, gene therapies, and RNA-based treatments, thereby propelling market growth.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Country-wise Insights

The section below highlights the projected growth rates of leading countries. Among these, South Korea is set to remain a highly lucrative market, exhibiting a CAGR of 7.2%. Japan and the United Kingdom are estimated to follow with CAGRs of 6.8% and 6.3%, respectively.

Countries Projected CAGR (2024 to 2034)
United States 5.4%
United Kingdom 6.3%
China 5.9%
South Korea 7.2%
Japan 6.8%

The asthma treatment industry can be observed in the subsequent tables, which focus on the leading economies, consisting of South Korea, Japan, the United Kingdom, China, and the United States. A comprehensive evaluation demonstrates that the United States has enormous potential for growth in the market.

Countries Market Values (2034)
United States US$ 8.3 billion
United Kingdom US$ 1.9 billion
China US$ 7.3 billion
South Korea US$ 3.0 billion
Japan US$ 5.2 billion

Rising Consumer Awareness to Boost Asthma Treatment Demand in the United States

The United States is set to dominate the market by 2034, surging at a CAGR of 5.4%. Asthma, a common non-communicable disease in the United States, accounts for around 73% of outpatient clinic visits, creating a wide target population for effective asthma therapeutics.

Established healthcare infrastructure and increasing asthma prevalence in the United States are the key factors propelling market growth. The United States is further projected to grow significantly due to improved government reforms, a rising geriatric population, increasing healthcare expenditure, and growing consumer awareness about lung diseases.

Growing Research and Development Activities Propelling Demand in China

By 2034, China is projected to grow substantially at a CAGR of 5.9%. Government initiatives, subsidies, and reimbursement policies to improve treatment quality, promote evidence-based practices, and reduce healthcare inconsistencies are influencing asthma therapy adoption in China.

Leading companies in China are focusing on research & development to innovate new therapeutic treatments, improve drug delivery systems, and understand asthma pathophysiology to reach wider customers.

The competitive asthma care market in China encourages innovation through collaborations and partnerships between industry stakeholders, academia, and patient advocacy groups.

Improvements in Treatment Options Spurring Growth in Japan

Japan is projected to propel due to factors such as high asthma prevalence, increased consumer awareness, and innovations in treatment options. Developments in biologic medications and targeted therapies, which offer improved efficacy and fewer side effects, are estimated to fuel growth in the market.

The market in Japan is further anticipated to be influenced by increased FDA endorsements and key market strategies such as collaboration, mergers, and partnerships among local and international companies. The market's development is projected to be accelerated by key players intensifying their geographical presence in emerging nations. By 2034, Japan is projected to reach US$ 5.2 billion.

Leading Pharmaceutical Companies in South Korea Paving the Road for Success

South Korea is home to several leading pharmaceutical companies specializing in asthma treatment, medication development, and manufacturing. These companies contribute to innovative asthma management therapies, propelling market growth in South Korea. South Korea is projected to reach a market valuation of US$ 3.0 billion in 2034.

South Korea's regulatory framework and favorable government reimbursement system encourage asthma treatment adoption, providing patients with a wide range of treatment options and fueling market reach.

South Korea is a leading center for asthma research and clinical trials, involving academic institutions, research centers, and healthcare organizations to develop new treatment methods.

Category-wise Insights

The segmented market analysis is included in the subsequent section. Based on comprehensive studies, the inhaler segment is dominating the product category. Likewise, the oral segment is commanding the route of administration category.

Segment Value CAGR (2024 to 2034)
Inhalers (Product) 4.8%
Oral (Route of Administration) 4.6%

Inhaler Segment Tops the Product Form Category

The inhalers segment, with its reliability, versatility, portability, and cost-effectiveness, is projected to lead the product segment by 2034. The growing prevalence of asthma and COPD, along with the need for emergency treatment alternatives, is propelling the segment’s growth.

The development of progressive products, such as Trelegy Ellipta, a triple therapy inhaler approved in the United States, is also projected to fuel segment growth. Based on product, the inhaler segment is set to surge at a CAGR of 4.8% by 2034.

Demand for Oral Route of Administration to Remain High Through 2034

Based on the route of administration, the oral segment is set to rise at 4.6% CAGR by 2034. The segment is projected to witness a leading growth rate from 2024 to 2034 due to its convenience and efficacy.

Oral medications, taken by mouth and absorbed through the digestive system, are well-preferred and easy to use, making them popular among patients and healthcare providers. The convenience, effectiveness, and versatility of the oral route of administration make the segment a valuable tool for managing asthma, boosting the segment's growth.

Competitive Landscape

Leading pharmaceutical companies are inclined toward research & development to surge their market reach while emerging biotech companies innovate targeted treatments to uphold their positions. Market growth relies on regulatory adherence, diagnostic research, strategic partnerships, and adapting to evolving consumer tastes.

For instance

  • In July 2023, Teva Pharmaceuticals, headquartered in Israel, partnered with Alvotech, enabling Teva to commercialize new biosimilars in the United States.
  • In March 2023, Teva Pharmaceuticals, headquartered in Israel, collaborated with Rimidi to start a respiratory patient monitoring program at Desert Oasis Healthcare in California, utilizing data from Teva's Digihaler System.
  • In August 2023, Areteia Therapeutics, a United States-based company, announced Phase 2 EXHALE-1 study results.
  • In October 2022, CHIESI USA, headquartered in the United States, partnered with Aptar Digital Health to develop a disease management platform for asthma and COPD patients, focusing on improving their quality of life and pushing demand for treatments.

Key Companies Profiled

  • Teva Pharmaceutical Industries Ltd.
  • GSK plc
  • Merck & Co., Inc.
  • F. Hoffmann-La Roche Ltd.
  • AstraZeneca
  • Boehringer Ingelheim International GmbH
  • Sanofi.
  • Koninklijke Philips N.V.
  • BD
  • Covis Pharma

Key Coverage in the Report

  • Asthma Drug and Pediatric Asthma Treatment Industry Size
  • Competitive Landscape in the Respiratory Therapeutic Market
  • Market Segmentation of Asthma Drugs
  • Industry Growth Factors for Respiratory Medicines
  • Asthma Prevalence and Market Outlook
  • Emerging Opportunities in the Asthma Management Sector
  • Respiratory Healthcare Industry Analysis
  • Asthma Medication Market Demand
  • Market Dynamics Influencing Patient Adherence and Healthcare Provider Preferences in Asthma Management
  • Analysis of Key Players and their Pipeline Products in the Asthma Treatment Industry
  • Evaluation of Healthcare Policies and Reimbursement Frameworks Affecting Asthma Medication Accessibility
  • Technological Developments and Innovations Fueling Personalized Asthma Therapy Approaches
  • Market Research on Pricing Strategies and Cost-effectiveness of Asthma Medications
  • Market Analysis of Asthma Treatment Options and Their Efficacy in Controlling Symptoms
  • Market Forecast for Asthma Care Products by Type, Delivery Method, and Region
  • Impact of Environmental Factors and Pollution on Asthma Prevalence and Treatment Market Growth

Asthma Treatment Market Segmentation by Category

By Drug Class:

  • Anti-inflammatory
  • Bronchodilators
  • Combination Therapy

By Product:

  • Inhalers
    • Dry Powder
    • Metered Dose
    • Soft Mist
  • Nebulizers

By Route of Administration:

  • Oral
  • Inhaled
  • Others

By Region:

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • Middle East and Africa

Frequently Asked Questions

How big is the asthma treatment market?

The market is set to reach US$ 28.0 billion in 2024.

What is the forecast for the market?

Demand for asthma treatment is slated to rise at a 5.1% CAGR by 2034.

What is the future of the asthma treatment market?

The market is set to reach US$ 46.0 billion in 2034.

Who are the key players in the market?

Teva Pharmaceutical Industries Ltd, GSK plc, Merck & Co.Inc, and AstraZeneca are the key players.

Which product form would lead the market?

The inhaler segment is estimated to hold a significant market share in 2024.

Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Product Life Cycle Analysis

    3.5. Supply Chain Analysis

        3.5.1. Supply Side Participants and their Roles

            3.5.1.1. Manufacturer

            3.5.1.2. Mid-Level Participants (Traders)

            3.5.1.3. Wholesalers and Distributors

        3.5.2. Value Added and Value Created at Node in the Supply Chain

        3.5.3. List of Raw Material Suppliers

        3.5.4. List of Existing and Potential Buyer’s

    3.6. Investment Feasibility Matrix

    3.7. Value Chain Analysis

        3.7.1. Profit Margin Analysis

        3.7.2. Wholesalers and Distributors

        3.7.3. Retailers

    3.8. PESTLE and Porter’s Analysis

    3.9. Regulatory Landscape

        3.9.1. By Key Regions

        3.9.2. By Key Countries

    3.10. Regional Parent Market Outlook

    3.11. Production and Consumption Statistics

    3.12. Import and Export Statistics

4. Global Market Analysis 2019 to 2023 and Forecast, 2024 to 2034

    4.1. Historical Market Size Value (US$ million) & Volume (Units) Analysis, 2019 to 2023

    4.2. Current and Future Market Size Value (US$ million) & Volume (Units) Projections, 2024 to 2034

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Drug Class

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ million) & Volume (Units) Analysis By Drug Class, 2019 to 2023

    5.3. Current and Future Market Size Value (US$ million) & Volume (Units) Analysis and Forecast By Drug Class, 2024 to 2034

        5.3.1. Anti-inflammatory

        5.3.2. Bronchodilators

        5.3.3. Combination Therapy

    5.4. Y-o-Y Growth Trend Analysis By Drug Class, 2019 to 2023

    5.5. Absolute $ Opportunity Analysis By Drug Class, 2024 to 2034

6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Product

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ million) & Volume (Units) Analysis By Product, 2019 to 2023

    6.3. Current and Future Market Size Value (US$ million) & Volume (Units) Analysis and Forecast By Product, 2024 to 2034

        6.3.1. Inhalers

            6.3.1.1. Dry Powder

            6.3.1.2. Metered Dose

            6.3.1.3. Soft Mist

        6.3.2. Nebulizers

    6.4. Y-o-Y Growth Trend Analysis By Product, 2019 to 2023

    6.5. Absolute $ Opportunity Analysis By Product, 2024 to 2034

7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Route of Administration

    7.1. Introduction / Key Findings

    7.2. Historical Market Size Value (US$ million) & Volume (Units) Analysis By Route of Administration, 2019 to 2023

    7.3. Current and Future Market Size Value (US$ million) & Volume (Units) Analysis and Forecast By Route of Administration, 2024 to 2034

        7.3.1. Oral

        7.3.2. Inhaled

        7.3.3. Others

    7.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2019 to 2023

    7.5. Absolute $ Opportunity Analysis By Route of Administration, 2024 to 2034

8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Region

    8.1. Introduction

    8.2. Historical Market Size Value (US$ million) & Volume (Units) Analysis By Region, 2019 to 2023

    8.3. Current Market Size Value (US$ million) & Volume (Units) Analysis and Forecast By Region, 2024 to 2034

        8.3.1. North America

        8.3.2. Latin America

        8.3.3. Western Europe

        8.3.4. Eastern Europe

        8.3.5. South Asia and Pacific

        8.3.6. East Asia

        8.3.7. Middle East and Africa

    8.4. Market Attractiveness Analysis By Region

9. North America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country

    9.1. Historical Market Size Value (US$ million) & Volume (Units) Trend Analysis By Market Taxonomy, 2019 to 2023

    9.2. Market Size Value (US$ million) & Volume (Units) Forecast By Market Taxonomy, 2024 to 2034

        9.2.1. By Country

            9.2.1.1. United States

            9.2.1.2. Canada

        9.2.2. By Drug Class

        9.2.3. By Product

        9.2.4. By Route of Administration

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Drug Class

        9.3.3. By Product

        9.3.4. By Route of Administration

    9.4. Key Takeaways

10. Latin America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country

    10.1. Historical Market Size Value (US$ million) & Volume (Units) Trend Analysis By Market Taxonomy, 2019 to 2023

    10.2. Market Size Value (US$ million) & Volume (Units) Forecast By Market Taxonomy, 2024 to 2034

        10.2.1. By Country

            10.2.1.1. Brazil

            10.2.1.2. Mexico

            10.2.1.3. Rest of Latin America

        10.2.2. By Drug Class

        10.2.3. By Product

        10.2.4. By Route of Administration

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Drug Class

        10.3.3. By Product

        10.3.4. By Route of Administration

    10.4. Key Takeaways

11. Western Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country

    11.1. Historical Market Size Value (US$ million) & Volume (Units) Trend Analysis By Market Taxonomy, 2019 to 2023

    11.2. Market Size Value (US$ million) & Volume (Units) Forecast By Market Taxonomy, 2024 to 2034

        11.2.1. By Country

            11.2.1.1. Germany

            11.2.1.2. United Kingdom

            11.2.1.3. France

            11.2.1.4. Spain

            11.2.1.5. Italy

            11.2.1.6. Rest of Western Europe

        11.2.2. By Drug Class

        11.2.3. By Product

        11.2.4. By Route of Administration

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Drug Class

        11.3.3. By Product

        11.3.4. By Route of Administration

    11.4. Key Takeaways

12. Eastern Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country

    12.1. Historical Market Size Value (US$ million) & Volume (Units) Trend Analysis By Market Taxonomy, 2019 to 2023

    12.2. Market Size Value (US$ million) & Volume (Units) Forecast By Market Taxonomy, 2024 to 2034

        12.2.1. By Country

            12.2.1.1. Poland

            12.2.1.2. Russia

            12.2.1.3. Czech Republic

            12.2.1.4. Romania

            12.2.1.5. Rest of Eastern Europe

        12.2.2. By Drug Class

        12.2.3. By Product

        12.2.4. By Route of Administration

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Drug Class

        12.3.3. By Product

        12.3.4. By Route of Administration

    12.4. Key Takeaways

13. South Asia and Pacific Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country

    13.1. Historical Market Size Value (US$ million) & Volume (Units) Trend Analysis By Market Taxonomy, 2019 to 2023

    13.2. Market Size Value (US$ million) & Volume (Units) Forecast By Market Taxonomy, 2024 to 2034

        13.2.1. By Country

            13.2.1.1. India

            13.2.1.2. Bangladesh

            13.2.1.3. Australia

            13.2.1.4. New Zealand

            13.2.1.5. Rest of South Asia and Pacific

        13.2.2. By Drug Class

        13.2.3. By Product

        13.2.4. By Route of Administration

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Drug Class

        13.3.3. By Product

        13.3.4. By Route of Administration

    13.4. Key Takeaways

14. East Asia Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country

    14.1. Historical Market Size Value (US$ million) & Volume (Units) Trend Analysis By Market Taxonomy, 2019 to 2023

    14.2. Market Size Value (US$ million) & Volume (Units) Forecast By Market Taxonomy, 2024 to 2034

        14.2.1. By Country

            14.2.1.1. China

            14.2.1.2. Japan

            14.2.1.3. South Korea

        14.2.2. By Drug Class

        14.2.3. By Product

        14.2.4. By Route of Administration

    14.3. Market Attractiveness Analysis

        14.3.1. By Country

        14.3.2. By Drug Class

        14.3.3. By Product

        14.3.4. By Route of Administration

    14.4. Key Takeaways

15. Middle East and Africa Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country

    15.1. Historical Market Size Value (US$ million) & Volume (Units) Trend Analysis By Market Taxonomy, 2019 to 2023

    15.2. Market Size Value (US$ million) & Volume (Units) Forecast By Market Taxonomy, 2024 to 2034

        15.2.1. By Country

            15.2.1.1. GCC Countries

            15.2.1.2. South Africa

            15.2.1.3. Israel

            15.2.1.4. Rest of Middle East and Africa

        15.2.2. By Drug Class

        15.2.3. By Product

        15.2.4. By Route of Administration

    15.3. Market Attractiveness Analysis

        15.3.1. By Country

        15.3.2. By Drug Class

        15.3.3. By Product

        15.3.4. By Route of Administration

    15.4. Key Takeaways

16. Key Countries Market Analysis

    16.1. United States

        16.1.1. Pricing Analysis

        16.1.2. Market Share Analysis, 2024

            16.1.2.1. By Drug Class

            16.1.2.2. By Product

            16.1.2.3. By Route of Administration

    16.2. Canada

        16.2.1. Pricing Analysis

        16.2.2. Market Share Analysis, 2024

            16.2.2.1. By Drug Class

            16.2.2.2. By Product

            16.2.2.3. By Route of Administration

    16.3. Brazil

        16.3.1. Pricing Analysis

        16.3.2. Market Share Analysis, 2024

            16.3.2.1. By Drug Class

            16.3.2.2. By Product

            16.3.2.3. By Route of Administration

    16.4. Mexico

        16.4.1. Pricing Analysis

        16.4.2. Market Share Analysis, 2024

            16.4.2.1. By Drug Class

            16.4.2.2. By Product

            16.4.2.3. By Route of Administration

    16.5. Germany

        16.5.1. Pricing Analysis

        16.5.2. Market Share Analysis, 2024

            16.5.2.1. By Drug Class

            16.5.2.2. By Product

            16.5.2.3. By Route of Administration

    16.6. United Kingdom

        16.6.1. Pricing Analysis

        16.6.2. Market Share Analysis, 2024

            16.6.2.1. By Drug Class

            16.6.2.2. By Product

            16.6.2.3. By Route of Administration

    16.7. France

        16.7.1. Pricing Analysis

        16.7.2. Market Share Analysis, 2024

            16.7.2.1. By Drug Class

            16.7.2.2. By Product

            16.7.2.3. By Route of Administration

    16.8. Spain

        16.8.1. Pricing Analysis

        16.8.2. Market Share Analysis, 2024

            16.8.2.1. By Drug Class

            16.8.2.2. By Product

            16.8.2.3. By Route of Administration

    16.9. Italy

        16.9.1. Pricing Analysis

        16.9.2. Market Share Analysis, 2024

            16.9.2.1. By Drug Class

            16.9.2.2. By Product

            16.9.2.3. By Route of Administration

    16.10. Poland

        16.10.1. Pricing Analysis

        16.10.2. Market Share Analysis, 2024

            16.10.2.1. By Drug Class

            16.10.2.2. By Product

            16.10.2.3. By Route of Administration

    16.11. Russia

        16.11.1. Pricing Analysis

        16.11.2. Market Share Analysis, 2024

            16.11.2.1. By Drug Class

            16.11.2.2. By Product

            16.11.2.3. By Route of Administration

    16.12. Czech Republic

        16.12.1. Pricing Analysis

        16.12.2. Market Share Analysis, 2024

            16.12.2.1. By Drug Class

            16.12.2.2. By Product

            16.12.2.3. By Route of Administration

    16.13. Romania

        16.13.1. Pricing Analysis

        16.13.2. Market Share Analysis, 2024

            16.13.2.1. By Drug Class

            16.13.2.2. By Product

            16.13.2.3. By Route of Administration

    16.14. India

        16.14.1. Pricing Analysis

        16.14.2. Market Share Analysis, 2024

            16.14.2.1. By Drug Class

            16.14.2.2. By Product

            16.14.2.3. By Route of Administration

    16.15. Bangladesh

        16.15.1. Pricing Analysis

        16.15.2. Market Share Analysis, 2024

            16.15.2.1. By Drug Class

            16.15.2.2. By Product

            16.15.2.3. By Route of Administration

    16.16. Australia

        16.16.1. Pricing Analysis

        16.16.2. Market Share Analysis, 2024

            16.16.2.1. By Drug Class

            16.16.2.2. By Product

            16.16.2.3. By Route of Administration

    16.17. New Zealand

        16.17.1. Pricing Analysis

        16.17.2. Market Share Analysis, 2024

            16.17.2.1. By Drug Class

            16.17.2.2. By Product

            16.17.2.3. By Route of Administration

    16.18. China

        16.18.1. Pricing Analysis

        16.18.2. Market Share Analysis, 2024

            16.18.2.1. By Drug Class

            16.18.2.2. By Product

            16.18.2.3. By Route of Administration

    16.19. Japan

        16.19.1. Pricing Analysis

        16.19.2. Market Share Analysis, 2024

            16.19.2.1. By Drug Class

            16.19.2.2. By Product

            16.19.2.3. By Route of Administration

    16.20. South Korea

        16.20.1. Pricing Analysis

        16.20.2. Market Share Analysis, 2024

            16.20.2.1. By Drug Class

            16.20.2.2. By Product

            16.20.2.3. By Route of Administration

    16.21. GCC Countries

        16.21.1. Pricing Analysis

        16.21.2. Market Share Analysis, 2024

            16.21.2.1. By Drug Class

            16.21.2.2. By Product

            16.21.2.3. By Route of Administration

    16.22. South Africa

        16.22.1. Pricing Analysis

        16.22.2. Market Share Analysis, 2024

            16.22.2.1. By Drug Class

            16.22.2.2. By Product

            16.22.2.3. By Route of Administration

    16.23. Israel

        16.23.1. Pricing Analysis

        16.23.2. Market Share Analysis, 2024

            16.23.2.1. By Drug Class

            16.23.2.2. By Product

            16.23.2.3. By Route of Administration

17. Market Structure Analysis

    17.1. Competition Dashboard

    17.2. Competition Benchmarking

    17.3. Market Share Analysis of Top Players

        17.3.1. By Regional

        17.3.2. By Drug Class

        17.3.3. By Product

        17.3.4. By Route of Administration

18. Competition Analysis

    18.1. Competition Deep Dive

        18.1.1. Teva Pharmaceutical Industries Ltd.

            18.1.1.1. Overview

            18.1.1.2. Product Portfolio

            18.1.1.3. Profitability by Market Segments

            18.1.1.4. Sales Footprint

            18.1.1.5. Strategy Overview

                18.1.1.5.1. Marketing Strategy

                18.1.1.5.2. Product Strategy

                18.1.1.5.3. Channel Strategy

        18.1.2. GSK plc

            18.1.2.1. Overview

            18.1.2.2. Product Portfolio

            18.1.2.3. Profitability by Market Segments

            18.1.2.4. Sales Footprint

            18.1.2.5. Strategy Overview

                18.1.2.5.1. Marketing Strategy

                18.1.2.5.2. Product Strategy

                18.1.2.5.3. Channel Strategy

        18.1.3. Merck & Co., Inc.

            18.1.3.1. Overview

            18.1.3.2. Product Portfolio

            18.1.3.3. Profitability by Market Segments

            18.1.3.4. Sales Footprint

            18.1.3.5. Strategy Overview

                18.1.3.5.1. Marketing Strategy

                18.1.3.5.2. Product Strategy

                18.1.3.5.3. Channel Strategy

        18.1.4. F. Hoffmann-La Roche Ltd

            18.1.4.1. Overview

            18.1.4.2. Product Portfolio

            18.1.4.3. Profitability by Market Segments

            18.1.4.4. Sales Footprint

            18.1.4.5. Strategy Overview

                18.1.4.5.1. Marketing Strategy

                18.1.4.5.2. Product Strategy

                18.1.4.5.3. Channel Strategy

        18.1.5. AstraZeneca

            18.1.5.1. Overview

            18.1.5.2. Product Portfolio

            18.1.5.3. Profitability by Market Segments

            18.1.5.4. Sales Footprint

            18.1.5.5. Strategy Overview

                18.1.5.5.1. Marketing Strategy

                18.1.5.5.2. Product Strategy

                18.1.5.5.3. Channel Strategy

        18.1.6. Boehringer Ingelheim International GmbH

            18.1.6.1. Overview

            18.1.6.2. Product Portfolio

            18.1.6.3. Profitability by Market Segments

            18.1.6.4. Sales Footprint

            18.1.6.5. Strategy Overview

                18.1.6.5.1. Marketing Strategy

                18.1.6.5.2. Product Strategy

                18.1.6.5.3. Channel Strategy

        18.1.7. Sanofi.

            18.1.7.1. Overview

            18.1.7.2. Product Portfolio

            18.1.7.3. Profitability by Market Segments

            18.1.7.4. Sales Footprint

            18.1.7.5. Strategy Overview

                18.1.7.5.1. Marketing Strategy

                18.1.7.5.2. Product Strategy

                18.1.7.5.3. Channel Strategy

        18.1.8. Koninklijke Philips N.V.

            18.1.8.1. Overview

            18.1.8.2. Product Portfolio

            18.1.8.3. Profitability by Market Segments

            18.1.8.4. Sales Footprint

            18.1.8.5. Strategy Overview

                18.1.8.5.1. Marketing Strategy

                18.1.8.5.2. Product Strategy

                18.1.8.5.3. Channel Strategy

        18.1.9. BD

            18.1.9.1. Overview

            18.1.9.2. Product Portfolio

            18.1.9.3. Profitability by Market Segments

            18.1.9.4. Sales Footprint

            18.1.9.5. Strategy Overview

                18.1.9.5.1. Marketing Strategy

                18.1.9.5.2. Product Strategy

                18.1.9.5.3. Channel Strategy

        18.1.10. Covis Pharma

            18.1.10.1. Overview

            18.1.10.2. Product Portfolio

            18.1.10.3. Profitability by Market Segments

            18.1.10.4. Sales Footprint

            18.1.10.5. Strategy Overview

                18.1.10.5.1. Marketing Strategy

                18.1.10.5.2. Product Strategy

                18.1.10.5.3. Channel Strategy

19. Assumptions & Acronyms Used

20. Research Methodology

Recommendations

Healthcare

Progesterone Market

Published : April 2024

Healthcare

Topical Pain Relief Market

Published : April 2024

Healthcare

Nitric Oxide Asthma Testing Market

Published : March 2023

Healthcare

Severe Asthma Treatment Market

Published : February 2023

Explore Healthcare Insights

View Reports